

# CITATION REPORT

List of articles citing

**Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia**

**DOI: 10.1007/s12325-018-0798-6**

**Advances in Therapy, 2018, 35, 1816-1829.**

**Source:** <https://exaly.com/paper-pdf/70622903/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
31	The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study. <i>BMJ Supportive and Palliative Care</i> , <b>2019</b> , 9, 373-380	2.2	3
30	A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga <sup>®</sup> ) to the reference biologic (Neulasta <sup>®</sup> ). <i>Journal of Oncology Pharmacy Practice</i> , <b>2022</b> , 28, 5-16	1.7	2
29	Contrasting Immunopathogenic and Therapeutic Roles of Granulocyte Colony-Stimulating Factor in Cancer. <i>Pharmaceuticals</i> , <b>2020</b> , 13,	5.2	4
28	Recent advances in the management of chemotherapy-induced neutropenia: biosimilar granulocyte colony-stimulating factor use in Italy. <i>Future Oncology</i> , <b>2020</b> , 16, 891-897	3.6	
27	Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , <b>2020</b> , 28, 5085-5097	3.9	4
26	Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure. <i>BioDrugs</i> , <b>2020</b> , 34, 255-263	7.9	8
25	Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 157, 103193	7	2
24	Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data. <i>Journal of Medical Economics</i> , <b>2021</b> , 24, 665-674	2.4	1
23	Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia <sup>®</sup> BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy. <i>Journal of Modern Oncology</i> , <b>2020</b> , 22, 77-84	0.3	1
22	Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 644187	5.6	3
21	Optimizing Dose-Adjusted EPOCH Chemotherapy with Long-Acting Granulocyte Colony-Stimulating Factor During the COVID-19 Epidemic. <i>Cancer Management and Research</i> , <b>2021</b> , 13, 3219-3225	3.6	
20	Chinese Herbal Medicine for Chemotherapy-Induced Leukopenia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 573500	5.6	0
19	Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors-A Breakthrough in the Treatment of Cancer Patients with Febrile Neutropenia. <i>Medicina (Lithuania)</i> , <b>2021</b> , 57,	3.1	0
18	The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck. <i>Journal of Modern Oncology</i> , <b>2021</b> , 23, 356-360	0.3	
17	Optimal Management of Chemotherapy-related Adverse Events. <i>The Korean Journal of Pancreas and Biliary Tract</i> , <b>2020</b> , 25, 46-54	0.2	1
16	Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment. <i>BMJ Supportive and Palliative Care</i> , <b>2021</b> ,	2.2	2
15	Approach and Management of Severe Infections in Neutropenic Patients. <b>2020</b> , 191-209		

14	Prevention of neutropenia as an important factor in successful chemotherapy for head and neck cancer. <i>Opuholi Golovy I Sei</i> , <b>2021</b> , 11, 72-82	0.2	1
13	Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database.. <i>Biology</i> , <b>2022</b> , 11,	4.9	1
12	Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia.. <i>Future Oncology</i> , <b>2022</b> ,	3.6	
11	Long-acting versus short-acting granulocyte colony-stimulating factors among cancer patients after chemotherapy in China: A systematic review and meta-analysis of randomized controlled trials.. <i>Medicine (United States)</i> , <b>2021</b> , 100, e28218	1.8	
10	Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.. <i>Supportive Care in Cancer</i> , <b>2022</b> , 1	3.9	
9	Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors. <i>Medicinski Podmladak</i> , <b>2022</b> , 73, 1-5	0	
8	ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. <b>2022</b> ,		2
7	Methotrexate-induced mucocutaneous ulceration. <b>2022</b> , 29, 101504		
6	Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit.		0
5	Effectiveness and Safety of Filgrastim (Neupogen) versus Filgrastim-aafi (Nivestim) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study.		0
4	Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement.		0
3	Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study. <b>2023</b> , 30, 107327482211402		0
2	Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis. <b>2023</b> , 28,		0
1	The reliability of Febrile Neutropenia after Chemotherapy (FENCE) scores in predicting granulocyte colony-stimulating factor breakthrough febrile neutropenia among patients with lymphoma undergoing first-cycle chemotherapy: A prospective observational study. 10,		0